Life Tech Mass Spec Revenues Rise 2 Percent in Q3; Firm Prepares to Transfer Arm to Danaher | GenomeWeb

This story originally ran on Oct. 28.

By Tony Fong

Life Technologies this week reported a 2 percent rise in its mass spectrometry business during its third quarter as it awaits transfer of the unit to Danaher.

Revenues from mass spec sales during the three months ended Sept. 30 climbed to $111 million from $109.2 million a year ago, before the merger between Applied Biosystems and Invitrogen creating Life Tech had been completed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.